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AbstrAct:
Tumorigenesis occurs due to synergistic interactions from a complex of signal 
transduction processes, including multiple onco-proteins and tumor suppressors 
such  as  Ras,  Myc,  PI3K/Akt/mTOR,  Her-2/Neu,  p53  and  PTEN.  Specifically,  the 
PI3K/Akt and mTOR pathways have been shown to play a pivotal role on the 
initiation and progression of malignancies, enhancing cell survival by stimulating 
cell proliferation, and inhibiting apoptosis. Therefore, it is critical to examine 
therapeutic agents that explicitly target both the PI3K/Akt and mTOR signaling 
cascades in diseases, such as Waldenstrom Macroglobulinemia (WM), that harbor 
activation of the PI3K/Akt pathway. We demonstrated that dual targeting of 
the PI3K and mTOR pathways by the novel inhibitor NVP-BEZ235, exhibited 
toxicity on WM cells by directly targeting the tumor clone and indirectly through 
an effect on the bone marrow milieu. These findings suggest that dual targeting 
of the PI3K and mTOR pathways is a better modality of targeted therapy for 
tumors that harbor activation of the PI3K/mTOR pathways, such as in WM.
IntroductIon
Waldenstrom Macroglobulinemia (WM) is a rare, 
low-grade, IgM secreting, lymphoplasmacytic lymphoma, 
characterized by the presence of lymphoplasmacytic cells 
in the bone marrow and IgM secretion in the peripheral 
blood. We have recently demonstrated that primary WM 
cells present with a constitutive activation of the PI3K/
Akt pathway, sustained by decreased expression of PTEN 
at the gene and protein levels, together with constitutive 
activation of Akt and mTOR, PI3K-downstream signaling 
cascades [1]. It has been clearly demonstrated that 
PI3K pathway plays a pivotal role on the initiation and 
progression of malignancies, enhancing cell survival by 
stimulating cell proliferation and inhibiting apoptosis [2-
6]. Signaling begins with the activation of receptor tyrosine 
kinases (RTKs). Upon activation by a ligand, RTKs engage 
and activate PI3K, which in turn converts membrane-
bound phosphatidylinositol (4,5)-bisphosphonate (PIP2) 
to phosphatidylinositol (3,4,5)-triphosphonate (PIP3). 
PIP3 then activates Akt by phosphorylation [7,8]. Akt acts 
to promote cell proliferation and survival, and regulates 
multiple signaling pathways that maintain cell cycle, 
proliferation, and resistance to apoptosis such as BAD, 
caspases, IKK, GSK3, Forkhead-related transcription 
factor 1 (FKHR1), eNOS, and mTOR [4,7,8]. The 
mammalian target of rapamycin (mTOR) kinase leads 
to cell growth and proliferation [9]. mTOR exists in two 
distinct functional complexes, mTORC1 and mTORC2. 
mTORC1 (rapamycin sensitive) consists of mTOR 
and Raptor; its activation results in phosphorylation of 
p70S6 and 4E-BP1. mTORC2 consists of mTOR and the 
rapamycin-insensitive companion of mTOR (Rictor), and 
it results in Akt phosphorylation [10-13].
We have previously shown that targeting mTOR 
leads  to  significant  clinical  activity  in  these  patients 
with up to 45% having partial remission when treated 
with a TORC1 inhibitor (RAD001, Novartis, NJ) [14]. 
However, patients did not have a complete remission, 
which indicates a mechanism of resistance to TORC1 
exists in WM. Subsequently, we inquired as to whether 
dual inhibition of PI3K/Akt and mTOR pathways could Oncotarget 2010; 1:  578 - 582 579 www.impactjournals.com/oncotarget
potentially show higher cytotoxic activity in WM cells 
compared to PI3K or mTOR inhibitors alone, and found 
that dual targeting of the PI3K and mTOR pathways 
by the novel inhibitor NVP-BEZ235 exhibited higher 
cytotoxicity on WM cells compared to inhibition of the 
PI3K or mTOR pathways alone. 
rAtIonAl for testIng the duAl 
PI3K/AKt And mtor InhIbItor In 
Wm cells
Reduced expression of PTEN appear to be one of 
the different genetic aberrations that leads to PI3K/Akt 
activation, responsible for fundamental cellular processes 
linked to tumorigenesis, such as cell-cycle regulation, cell 
proliferation and survival, cell adhesion and migration, 
and  angiogenesis  [7,8,15,16].  We  identified  that  the 
expression of PTEN at gene level and protein level is 
lower in WM patients compared to control CD19+ cells. 
PTEN inactivating mutation or altered methylation status 
have not been described in WM, suggesting the possible 
role of epigenetics in silencing PTEN expression. For 
example, low PTEN levels could result from the de-
regualted expression of microRNAs (miRNAs). miRNAs 
constitute a class of small, non-coding, 18-24 nucleotide 
RNAs,  described  for  the  first  time  in  the  nematode 
Caenorabditis elegans [17]. To date, more than 300 
miRNAs have been discovered in humans [18]. miRNAs 
act as negative regulators of gene expression by binding 
to the 3’ untranslated region (UTR) of the target mRNAs 
with partial sequence complementarity and leading to 
translational repression [19]. By repressing several target 
mRNAs, mature miRNAs play a pivotal role in regulating 
development, cell differentiation, apoptosis, and cell 
proliferation [20]. We have previously performed miRNA 
profiling in WM [21], and found that miRNA-494 and 
-542-3p are over-expressed in WM patients as compared 
to the normal cellular counterpart, suggesting a possible 
role of miRNAs in silencing PTEN gene expression, since 
PTEN represents a predicted target for both miRNA-494 
and -542-3p.
It is known that PTEN acts as negative regulator 
of Akt and mTOR [7], therefore, we subsequently 
confirmed  that  primary  WM  cells  present  with  higher 
p-Akt and downstream p-mTOR protein levels compared 
to their normal cellular counterpart together with a higher 
expression of rictor and raptor, two different components 
of the protein kinase mTOR. These findings provide the 
biological preclinical evidence for testing a dual PI3K/
Akt and mTOR inhibitor in tumors harboring constitutive 
activation of PI3K/Akt and mTOR signaling cascades, 
such as WM.
duAl InhIbItIon of PI3K And 
mtor PAthWAys better tArget 
sIgnAlIng cAscAdes In Wm cells 
As comPAred to the ActIvIty 
exerted by PI3K or mtor 
InhIbItors used As sIngle Agents
The efficacy of the dual NVP-BEZ235 in targeting 
Akt and mTOR pathways cells has been recently proven 
in WM cells, as well as in other IgM-secreting low-
grade lymphoma cell lines, where the compound was 
able to specifically inhibit phosphorylation of Akt, and 
downstream GSK3α/β and ribosomal protein S6 in a dose 
dependent manner in the WM cells, together with inhibited 
phosphorylation of mTOR, as well as of the downstream 
targets p70S6 and 4EBP1. In addition, inhibition of both 
Akt and mTOR kinase activities were also documented. 
mTOR represents a large protein kinase that exists as two 
different entities within cells: one that contains mTOR 
and raptor and another containing mTOR and rictor. 
The raptor-mTOR complex is sensitive to the mTOR 
inhibitor rapamycin, while the rictor-containing complex 
is rapamycin-insensitive [4-6]  Notably, NVP-BEZ235 
has been able to target both rictor and raptor in the context 
of mTORC1 and mTORC2 complexes indicating that this 
may result in down-regulating the rictor positive feedback 
loop on Akt activation [6]. Moreover while rapamycin 
inhibited raptor and did not target rictor, leading to 
phospho(p)-Akt up-regulation, NVP-BEZ235 induced 
significant  p-Akt  inhibition  resulting  from  the  dual 
targeting of both rictor and raptor. Interestingly, NVP-
BEZ235 was equally or more effective in downregulating 
the mTOR-downstream targeted proteins p-p70S6 and 
p-4EBP1 compared to either PI3K or mTOR inhibitors 
when used alone.
nvP-beZ235-dePendent InhIbItIon 
of AKt And mtor sIgnAlIng 
cAscAdes leAds to toxIcIty In Wm 
cells, suPPorted by InductIon of 
APoPtosIs And cell cycle Arrest 
In treAted cells
It is known that both PI3/Akt and mTOR pathways 
regulate cell growth and proliferation [22-25]; recent report 
indicates the efficacy of NVP-BEZ235 in inducing toxicity 
and reducing DNA synthesis in WM cells, supported by 
caspase-9, caspase-8, caspase-3, and PARP cleavage. 
Moreover, NVP-BEZ235 induced down-modulation of 
the anti-apoptotic protein Mcl-1, with an increased release 
of the second mitochondria-derived activator of caspases 
(Smac/DIABLO) from the mitochondria to the cytosol. In 
addition, inhibition of the inhibitor of apoptosis protein 
(c-IAP) was observed in WM cells exposed to dual Oncotarget 2010; 1:  578 - 582 580 www.impactjournals.com/oncotarget
inhibition of PI3K/Akt and mTOR pathways, based on 
the ability of Smac/DIABLO to abrogate the protective 
effects of IAPs [26]. In addition, NVP-BEZ235 has been 
shown to target forkhead box (FoxO) transcription factors, 
leading to cell cycle arrest in WM cells. Several reports 
indicate that FoxOs represent down-stream effectors 
of the PI3K/AKT pathway, and that phosphorylation of 
AKT leads to nuclear export and cytoplasm retention of 
phosphorylated FoxOs, with consequent inhibition of their 
transcriptional activity [27,28]. Notably, NVP-BEZ235-
treated cells presented with inhibition of AKT-dependent 
p-FoxO1/O4/O3 expression; together with up-regulation 
of cell cycles inhibitors p27kip1 and p21waf1, leading to G1 
cell cycle arrest and reduction of the S phase in WM cells 
exposed to the dual PI3K/Akt and mTOR inhibitor.
duAl InhIbItIon of PI3K/AKt 
And mtor PAthWAys results In 
tArgetIng Wm cells even In the 
context of bone mArroW mIlIeu
It is important to highlight the role of NVP-BEZ235 
in targeting lymphoplasmacytic WM cells in the context 
of bone marrow (BM) microenvironment. BM milieu is 
represented by several cytotypes, including endothelial 
cells,  fibroblasts,  osteoblasts,  osteoclasts,  macrophages, 
and others that have been demonstrated to support tumor 
growth and to induce drug resistance in malignant cells 
[24,29]. Notably, the anti-tumor activity of NVP-BEZ235 
against WM cells in the context of the BM milieu has 
been tested and validated both in vivo and in vitro. By 
co-culturing WM cells and primary BM stromal cells 
isolated from patients with WM, we have demonstrated 
that NVP-BEZ235 abrogated BMSC adhesion-induced 
phosphorylation of Akt and mTOR in WM cells, indicating 
that NVP-BEZ235 exerts its anti-tumor activity even when 
WM cells were in contact with the BM milieu. Importantly, 
dual inhibition of PI3K/Akt and mTOR pathways targeted 
rictor and raptor in WM cells, even when cultured in 
presence of BMSCs which induced up-regulation of raptor 
but not rictor. In addition, NVP-BEZ235 has been proven 
to inhibit adhesion and migration of WM cells to BMSCs, 
supported by inhibited phosphorylation of focal adhesion 
kinase, paxillin and cofilin, important proteins which act 
figure 1.
dual inhibition of PI3/Akt and mtor signaling cascades targets Wm cells alone and Wm 
cells in the context of bone marrow microenvironment
figure 1: dual inhibition of PI3/Akt and mtor signaling cascades targets Wm cells alone and Wm cells in the context 
of bone marrow microenvironmentOncotarget 2010; 1:  578 - 582 581 www.impactjournals.com/oncotarget
as key regulators of adhesion and cell migration. In vivo 
assays have been performed in order to better define and 
validate the anti-tumor activity of NVP-BEZ235 in the 
context of BM milieu and it has been demonstrated that 
treatment of WM cells with NVP-BEZ235 resulted in a 
significant inhibition of WM cells homing to the BM in 
vivo. A schematic representation of NVP-BEZ235 effects 
on WM cells is provided in Figure 1.
conclusIon
Primary WM cells show constitutive activation 
of the PI3K/Akt and mTOR pathways, supported by 
decreased expression of PTEN. We have recently 
demonstrated that dual targeting of the PI3K and mTOR 
pathways by the novel inhibitor NVP-BEZ235 exhibited 
higher cytotoxicity on WM cells compared to inhibition 
of the PI3K or mTOR pathways alone, leading to WM 
cell toxicity, even when WM cells are cultured in the 
presence of BMSCs, both in vitro and in vivo. These 
studies therefore show that dual targeting of the PI3K and 
mTOR pathways is a better modality of targeted therapy 
for tumors that harbor activation of the PI3K/mTOR 
pathway, such as in WM. 
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